Diabetes Obes Metab 2013;15:770-3.ArticlePubMed 113
FDA Status: Approved for type 2 diabetes and chronic weight management How It Works: Stimulates GLP-1 receptors, reduces hunger, slows gastric emptying, and enhances insulin release Common Side Effects: Nausea, constipation, diarrhea, and mild gastrointestinal upset Typical Weight Loss Results: On average, users can lose 1015% of their body weight over time with proper lifestyle changes Semaglutide set the standard for GLP-1based therapies, helping millions worldwide achieve sustainable weight loss and metabolic improvement
(eds) Principles of Biochemistry (Pearson Press, 2006)
By mitigating metabolic risks before conception, GLP-1RAs may also indirectly reduce the incidence of future gestational complications, such as gestational diabetes mellitus (GDM)
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3